About SelectMDx:

 

SelectMDx is a National Comprehensive Cancer Network (NCCN) approved biomarker designed for patients who have an abnormal PSA and/or DRE who are being considered for a prostate biopsy. 

 

Unlike PSA, which is a measurement that is specific to the prostate but not necessarily prostate cancer, SelectMDx has been shown in research to more accurately assess an individual's risk of having prostate cancer, and more specifically, clinically significant prostate cancer (greater than or equal to Gleason 7).

 

This is done by simply collecting a sample of urine after a digital rectal examination (physical examination of ones prostate by their health care provider). 

​

Patient Resources:

​

Below are several resources designed to help patients and their family better understand how SelectMDx is used in a clinical setting, including a video as well as downloadable brochures. 

​

PCMs Brochure

This brochure, designed by pcmarkers.com, will help patients and their family further understand the test. 

Download File

MDXHealth Brochure

This brochure, designed by MDXHeatlh, will help patients and their family further understand the test. 

Download File

SelectMDX Sample Report

This sample report will help patients and their families understand how the results for this test are presented. 

View Report